Tech Company Financing Transactions

Tyra Biosciences Funding Round

Tyra Biosciences closed a $106 million Series C financing round on 4/2/2021. Investors included Nextech Invest, Alta Partners and Boxer Capital.

Transaction Overview

Company Name
Announced On
4/2/2021
Transaction Type
Venture Equity
Amount
$106,000,000
Round
Series C
Proceeds Purpose
It will use the series C financing to ramp up its drug discovery technology, dubbed SNAP, as well as advance a pipeline of small molecules, with plans to pick its first development candidate this year and push it into the clinic next year.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
2333 State St. 201
Carlsbad, CA 92008
USA
Phone
Undisclosed
Email Address
Overview
Tyra Biosciences is a biotechnology company targeting new pathways of acquired resistance in oncology with purpose-built drugs.
Profile
Tyra Biosciences LinkedIn Company Profile
Social Media
Tyra Biosciences Company Twitter Account
Company News
Tyra Biosciences News
Facebook
Tyra Biosciences on Facebook
YouTube
Tyra Biosciences on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Todd Harris
  Todd Harris LinkedIn Profile  Todd Harris Twitter Account  Todd Harris News  Todd Harris on Facebook


 

 

Browse more venture capital transactions:

Prev: 4/2/2021: BrightPlan venture capital transaction
Next: 4/2/2021: Lowkey venture capital transaction

 

Share this article

 


About Our VC Transactions Data

Our team works diligently to document every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary